Cyclic peptides have a special power in the therapeutic space — they’re larger and more specific than small molecules, and more permeable and cost-effective than antibodies. These qualities enable them to conquer two of the biggest challenges in modern drug development: prosecuting flat intracellular protein-protein interactions (PPIs) and achieving oral… Read More
Cyclic peptides have a special power in the therapeutic space — they’re larger and more specific than small molecules, and more permeable and cost-effective than antibodies. These qualities enable them to conquer two of the biggest challenges in modern drug development: prosecuting flat intracellular protein-protein interactions (PPIs) and achieving oral… Read More
Novo Nordisk has announced a strategic partnership with OpenAI that it hopes will place the company at the forefront of AI transformation in healthcare and help it bring new and better treatment options to patients faster. The partnership will apply advanced AI capabilities to analyse complex datasets,… Read More
DDW Deputy Editor Diana Turner speaks to the team behind an ambitious project to identify a novel drug target for endometriosis by the end of the year. The Advanced Research & Invention Agency (ARIA), through its AI Scientist programme, has awarded a £500,000 grant to fund a collaboration… Read More
Eli Lilly and Insilico Medicine have announced a drug discovery collaboration that uses Insilico’s AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas. The agreement grants Lilly an exclusive worldwide license for the development, manufacturing, and commercialisation of potentially best-in-class, novel… Read More
Roche now operates the pharmaceutical industry’s largest announced hybrid-cloud AI factory, totalling more than 3,500 GPUs, following an expansion of its global AI infrastructure. The company has deployed a large-scale AI factory powered by a full stack of the latest-generation NVIDIA accelerated computing and AI, marking the… Read More
This DDW guide explores the latest advancements in cancer research, including an overview of recent market developments, how to selectively degrade essential proteins, the potential of KRAS inhibitors and novel approaches to radiotherapy. Sponsored by Copyright 2022 Drug Discovery World. Read More
Insilico Medicine and China Medical System (CMS) have announced a series of AI‑empowered drug discovery collaborations in the fields of central nervous system and autoimmune diseases. According to the collaboration agreement, the parties will combine Insilico Medicine’s AI-enabled drug discovery and development capabilities with CMS’s… Read More
Deep tech company Pharmacelera has raised $6 million in an investment round to help accelerate its expansion in the United States and grow its platform. Pharmacelera uses its proprietary quantum mechanics and artificial intelligence (QaiM) algorithms to find novel and diverse molecular candidates across the chemical “exaSpace”. The company says its algorithms can generate… Read More
“How AI is transforming drug discovery” is an exclusive guide published by DDW that examines the challenges and opportunities this technology is presenting throughout the industry. It features stories on how AI is shaping drug discovery, how RNA-targeted drug discovery is being pioneered by AI and how the technology… Read More
How will preclinical discovery and clinical trials change in the coming year? And what role will regulators play? Diana Turner asks industry leaders for their predictions for 2026. A number of innovations are predicted to influence R&D in 2026, in both preclinical and clinical trials, including… Read More
AI drug discovery company Oxford Drug Design has successfully completed in vivo validation of a novel therapeutic approach targeting multiple tumour types. In studies using a genetically engineered mouse model that replicates the earliest mutational events in colorectal cancer, Oxford Drug Design’s lead compound demonstrated statistically significant anti-tumour… Read More
Which drug modalities will dominate the market, and which global regions will be most influential? Diana Turner asks industry leaders for their predictions for 2026. The opportunities and challenges facing biotech and biopharma in 2026 are concisely summarised by Dr Kevin Land, Executive Medical Director Biotherapies… Read More
For the third year running DDW is organising a series of seminars at SLAS International Conference and Exhibition. Based on the SLAS2026 theme of Catalyze Discovery, these will be available to visitors of SLAS2026 (7-11 February 2026, Boston, USA). The programme – Creating Cures: The role… Read More
In this webinar, hosted by DDW, Benchling provides an exclusive readout of what biotech leaders need to know heading into 2026 — and how 100 AI frontrunners are translating AI into real scientific impact. Get a rare, upfront look at what the most advanced biotech teams are actually doing with… Read More
How big a role will AI play in the coming year? Diana Turner asks industry leaders for their predictions. As with all sectors, the role of artificial intelligence (AI) in drug discovery is expected to significantly increase in 2026 and beyond. Richard Young, CSO… Read More
